Next Article in Journal
Eyeing up the Future of the Pupillary Light Reflex in Neurodiagnostics
Next Article in Special Issue
Percutaneous, Imaging-Guided Biopsy of Bone Metastases
Previous Article in Journal
Impact on Clinical Management of After-Hours Emergent or Urgent Breast Ultrasonography in Patients with Clinically Suspected Breast Abscesses
Previous Article in Special Issue
Reporting and Handling of Indeterminate Bone Scan Results in the Staging of Prostate Cancer: A Systematic Review
Open AccessCase Report

Dosimetry-Based Consideration on Remission and Relapse after Therapy with 223Ra-Dichloride in Castration-Resistant Prostate Cancer (CRPC) with Bone Metastases. A Case Report

1
Nuclear Medicine Department, “S. Camillo-Forlanini” General Hospital, 00152 Rome, Italy
2
Medical Physics Unit, “Policlinico Umberto I” University Hospital, 00161 Rome, Italy
3
Radiology, “S. Camillo-Forlanini” General Hospital, 00152 Rome, Italy
*
Author to whom correspondence should be addressed.
Diagnostics 2018, 8(1), 18; https://doi.org/10.3390/diagnostics8010018
Received: 29 January 2018 / Revised: 20 February 2018 / Accepted: 24 February 2018 / Published: 27 February 2018
(This article belongs to the Special Issue Imaging of Bone Metastases in Oncology)
  |  
PDF [2169 KB, uploaded 27 February 2018]
  |  

Abstract

Here, we present the case of a 64-year-old male patient diagnosed with castration-resistant prostate cancer (CRPC) with bone metastasis, treated with abiraterone prednisone/prednisolone in combination with 223Ra-dichloride therapy, who had remission and a subsequent relapse of bone metastasis on repeated bone scans after therapy. We also discuss the possibility of continuing the 223Ra-dichloride therapy over the six planned administrations by administering other cycles at the same dose or at higher doses, if shown to be devoid of a significant increase in side effects, based on dosimetry considerations. View Full-Text
Keywords: prostate cancer; bone scan; bone metastasis; 223Ra-dichloride therapy prostate cancer; bone scan; bone metastasis; 223Ra-dichloride therapy
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Mangano, A.M.; Pacilio, M.; Ialongo, P.; Semprebene, A.; Ventroni, G.; Mango, L. Dosimetry-Based Consideration on Remission and Relapse after Therapy with 223Ra-Dichloride in Castration-Resistant Prostate Cancer (CRPC) with Bone Metastases. A Case Report. Diagnostics 2018, 8, 18.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Diagnostics EISSN 2075-4418 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top